The Acromegaly Market is expected to show positive growth in the forecast period (2022–2032) due to the development of well-designed, randomized, controlled non-crossover trials with potential benefits. Moreover, the shortfall of approved therapy might provide suitable space for emerging therapies.
Acromegaly Market Report gives readers a thorough assessment of key market drivers, restraints, prospects, opportunities, restraints, current trends, and technological and industrial breakthroughs that will influence market growth. This Acromegaly Market report research conducts a careful market evaluation and provides a professional analysis of the industry taking into account market development, present market circumstances, and forecasts for the future. The market driving factors, market overview, industry volume, and market share are also highlighted in this Acromegaly Market report analysis.
Key takeaways from Acromegaly Market Research Report
- As per the DelveInsight’s estimate, the total number of prevalent cases of acromegaly in 2017 were found to be 61,022 in the 7MM.
- As per DelveInsight’s analysis, 57,971 acromegaly cases originated from pituitary adenomas and 3,051 from benign tumors at other sites in 2017.
- According to DelveInsight’s analysis, majority of the cases of Acromegaly is originated with adenomas at Pituitary gland and rest are because of benign tumor at other sites.
- Leading Acromegaly Companies such as Amryt, Chiasma, Recordati, Novartis Pharmaceuticals, Sun Pharma, Crinetics Pharmaceuticals, Camurus, Ionis Pharmaceuticals, and many others
- The promising Acromegaly therapies in the pipeline include Octreotide capsules, Veldoreotide, CAM2029, CRN00808, IONIS-GHR-LRx, ATL1103, MTD201, and many others
Know which therapies are expected to grab major Acromegaly Market Share @ Acromegaly Market Research Report
Acromegaly Overview
Acromegaly is a hormonal disorder that results from the availability of excessive growth hormone (GH) in the body, which is produced by the pituitary gland (a small gland in the brain). In acromegaly, the pituitary produces an immoderate amount of GH, which is resulted from benign or noncancerous tumors on the pituitary. These benign tumors are called Adenomas.
Common signs and symptoms of acromegaly are enlarged hands and feet. For example, patients are not able to put on rings that used to fit, and the shoe size has progressively increased. It may also cause gradual changes in the face shape, such as a protruding lower jaw and brow bone, an enlarged nose, thickened lips, and wider spacing between the teeth.
Surgery is the treatment of choice for all microadenomas as well as macroadenomas, causing a mass effect. Debulking of macroadenomas without mass effect can also be done and has been described as a modality to allow for better response to medical treatment even if a surgical cure is not likely. The best predictors of surgical cure include smaller tumor size, lower levels of GH/IGF-1, and absence of invasion of surrounding structures such as the cavernous sinus. All of these drugs are synthetic somatostatin and bind to somatostatin receptors.
Acromegaly Epidemiology Insights
Acromegaly is a very rare disorder caused, in most cases, by a tumor of the pituitary gland that produces too much growth hormone (GH). Nearly all pituitary tumors, including those that cause acromegaly, are benign, and not malignant. However, they can become quite large and expand beyond the normal confines of the pituitary gland.
Acromegaly Epidemiology Segmentation in the 7MM
- Total Acromegaly Prevalent Population
- Acromegaly Origin-based Prevalent Population
- Acromegaly Diagnosed Cases
- Acromegaly Treatable Cases
- Acromegaly Diagnosed Cases Based on Type
For further information of this report to understand which factors are driving Acromegaly Epidemiology trends @ Acromegaly Epidemiological Insights
Acromegaly Treatment Market
The current treatment method for Acromegaly is focused on preventing the tumor compression of surrounding tissues by excising the diseases causing areas, and on reducing GH and IGF-1 levels to normal. Although, the primary treatment method for Acromegaly is transsphenoidal surgery, although all the patients are not eligible for surgery. Patients diagnosed with microadenomas and those with macroadenomas not close to other key structures in the brain, such as the nerves supplying the eyes or nearby blood vessels, are recommended for surgery. The cure rate of surgery is about 80% for microadenomas and 40‒50% for macroadenomas.
Acromegaly Pipeline Companies
- Amryt
- Chiasma
- Recordati
- Novartis Pharmaceuticals
- Sun Pharma
- Crinetics Pharmaceuticals
- Camurus
- Ionis Pharmaceuticals, and many others
Acromegaly Market Insights
As per the literature reviews by Lim et al., titled “The role of combination medical therapy in the treatment of acromegaly,” pegvisomant and SSA combination has demonstrated good biochemical control in the majority of patients, and may allow individual drug dosage reductions, but patients require close monitoring for liver enzyme elevations. The combination of cabergoline, to SSA is relatively well tolerated and most likely to be effective in patients with very mild IGF-1 elevations. It was also found that the combination of pegvisomant and cabergoline may be useful in a select group of patients with mild IGF-1 elevations, particularly in the setting of intolerance to SSA or when the cost of SSA-Peg therapy is prohibitive.
Learn more about the Acromegaly Therapies in clinical trials @ Drugs for Acromegaly Treatment
Acromegaly Emerging Therapies
The emerging therapies for the treatment of Acromegaly includes Octreotide capsules (Chiasma Pharma), Veldoreotide (Strongbridge Biopharma), CAM2029 (Camurus), CRN00808 (Crinetics Pharmaceuticals), IONIS-GHR-LRx (Ionis Pharmaceuticals), ATL1103 (Antisense Therapeutics), and MTD201 (Midatech). Octreotide capsules have been granted orphan designation in the US and the European Union for the potential treatment of Acromegaly.
Scope of the Acromegaly Market Research Report
- Coverage- 7MM
- Study Period- 2019-2032
- Forecast Period- 2022-2032
- Acromegaly Companies such as Amryt, Chiasma, Recordati, Novartis Pharmaceuticals, Sun Pharma, Crinetics Pharmaceuticals, Camurus, Ionis Pharmaceuticals, and many others
- Acromegaly therapies- Octreotide capsules, Veldoreotide, CAM2029, CRN00808, IONIS-GHR-LRx, ATL1103, MTD201, and many others
- Acromegaly Therapeutic Assessment- Current marketed and emerging therapies
- Acromegaly Market Dynamics- Acromegaly Market Drivers and Barriers
- Competitive Intelligence Analysis- SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Acromegaly Market Access and Reimbursement
Discover more about Acromegaly Medications in development @ Acromegaly Clinical Trials
Table of Content
1. Key Insights
2. Acromegaly Executive Summary
3. Competitive Intelligence Analysis
4. Acromegaly: Market Overview at a Glance
5. Acromegaly: Disease Background and Overview
6. Patient Journey
7. Acromegaly Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Acromegaly Unmet Needs
10. Key Endpoints of Acromegaly Treatment
11. Acromegaly Marketed Products
12. Acromegaly Emerging Therapies
13. Acromegaly: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Acromegaly Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. Acromegaly Market Drivers
19. Acromegaly Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Get in touch with our Business Executive @ Acromegaly Market Trend
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
